Shots:
DESRES to receive an up front of $60M & is eligible to receive development and commercial milestones of ~$475M along with royalties
DES-7114 is a highly selective small-molecule inhibitor of the ion channel protein Kv1.3 & has recently completed P-I clinical trials in healthy volunteers. The therapy showed efficacy in preclinical models of multiple chronic inflammatory and autoimmune disease, including UC, CD, & AD
The utilization of special-purpose supercomputers that have been developed by DESRES to undertake ultra-high-speed, atomically detailed simulations of the three-dimensional motion of physiologically and pharmaceutically relevant molecules enabled the construction of DES-7114
Ref: PRNewswire | Image: Lilly
